Señales en vivo de GTH | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 mar 2024 @ 16:00):

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment...

Stats
Volumen de hoy	412 603
Volumen promedio	51 864.00
Capitalización de mercado	127.29M
EPS	$0 ( 2024-01-18 )
Próxima fecha de ganancias	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.110
ATR14	$0.00400 (0.10%)

Genetron Holdings Limited Correlación

10 Correlaciones Más Positivas
VCTR	0.946
CLGN	0.946
ENTF	0.938
INCR	0.929
TZPS	0.927
VITL	0.924
FANG	0.923
ALSA	0.921
CITE	0.919
SVFAU	0.919

10 Correlaciones Más Negativas
NLSP	-0.931
HCDIP	-0.924
UONEK	-0.921
LUCD	-0.92
SHEN	-0.918
EMBC	-0.917
PEAR	-0.914
FRHC	-0.914
AKTX	-0.91
MVIS	-0.91

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genetron Holdings Limited Finanzas

Annual	2022
Ingresos:	$650.71M
Beneficio Bruto:	$281.43M (43.25 %)
EPS:	$-9.53

FY	2022
Ingresos:	$650.71M
Beneficio Bruto:	$281.43M (43.25 %)
EPS:	$-9.53

FY	2021
Ingresos:	$531.95M
Beneficio Bruto:	$337.97M (63.53 %)
EPS:	$-4.73

FY	2020
Ingresos:	$424.49M
Beneficio Bruto:	$260.22M (61.30 %)
EPS:	$-50.90

Financial Reports:

No articles found.

Genetron Holdings Limited

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

Actualizaciones en tiempo real para Genetron Holdings Limited [GTH]

Upcoming Earnings Alert